Source:http://linkedlifedata.com/resource/pubmed/id/12962368
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-9-9
|
pubmed:abstractText |
We investigated the efficacy of Mo17-1A to improve important immunological parameters in vivo and in vitro in colorectal cancer (CRC) patients receiving no second-line treatment. Eighteen CRC patients stage Dukes' C were treated postoperatively with 5 doses of Mo17-1A. Peripheral blood mononuclear cells (PBMC) were analyzed for proliferative responses and cytolytic activity. Serum levels of cytokines were determined during treatment. Enhancement in the proliferative activity of patients' T cells, improvement in their lymphocytes' killing ability of natural killer (NK) and lymphokine-activated killer (LAK) sensitive tumor targets, and an in vivo increase in serum levels of interleukin (IL)-2, IL-12, IL-15, interferon (IFN)-gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF) were noted. We conclude that treatment of CRC patients with Mo17-1A partially restores deficient cellular immune responses and the secretion of cytokines with immuno-enhancing properties. The development of novel immunotherapeutic protocols using combinations of Mo17-1A with stimuli that enhance the lytic capacity of effector cells (e.g. cytokines), may improve clinical responses in these types of patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Edrecolomab,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1120-009X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
387-93
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12962368-Antibodies, Monoclonal,
pubmed-meshheading:12962368-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:12962368-Antineoplastic Agents,
pubmed-meshheading:12962368-Chemotherapy, Adjuvant,
pubmed-meshheading:12962368-Colorectal Neoplasms,
pubmed-meshheading:12962368-Cytotoxicity, Immunologic,
pubmed-meshheading:12962368-Female,
pubmed-meshheading:12962368-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:12962368-Humans,
pubmed-meshheading:12962368-Interferon-gamma,
pubmed-meshheading:12962368-Interleukins,
pubmed-meshheading:12962368-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:12962368-Killer Cells, Natural,
pubmed-meshheading:12962368-Male,
pubmed-meshheading:12962368-Middle Aged,
pubmed-meshheading:12962368-Pilot Projects
|
pubmed:year |
2003
|
pubmed:articleTitle |
Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
|
pubmed:affiliation |
Department of Animal and Human Physiology, School of Biology, University of Athens, Ilissia, Athens, Greece. rtsitsil@biol.uoa.gr
|
pubmed:publicationType |
Journal Article,
In Vitro
|